Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $351.8M rose 40.7% year over year, ahead of the +30.7% change in trailing-twelve-month research & development. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at +29.9% a year.

Context

  • Research & development amounted to 35.5% of revenue in FY2025, up 4.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +40.7% holds above the trailing-twelve-month pace of +30.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$351.8M+7.7% QoQ
Last fiscal yearDec 2025
$1.02B+38.9% YoY
LTMSep 2026
$1.23B+30.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.7%——
1 year+38.9%——
3-year CAGR+29.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
1.02B USD
Year-over-year change
+38.9%
4-year CAGR
+32.6%

Research & Development vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's LTM Sep 2026 research & development of $1.23B is the highest of the 10 companies compared; the peer median is $162.51M.
  • Its year-over-year change of +30.7% is the 2nd highest of 10, against a peer median of -3.5%.
  • Research & development amounts to 33.3% of revenue for NBIX, versus a peer median of 25.4%.
NBIX Competitors Peer median
Research & Development for NBIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.23B +30.7%+29.9%33.3%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$623.61M -26.8%+9.9%13.2%
BHVNBiohaven Ltd.LTM Jun 2026$467.76M -32.9%+13.3%—
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$319.46M -7.3%-3.1%26.6%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$187.86M -3.5%+46.8%24.2%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$126.09M +18.1%+12.5%15.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.93M +58.7%+118.3%539.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$101.99M +14.6%+8.4%46.8%
GHRSGH Research PLCLTM Mar 2026$43.27M +26.5%+23.7%—
Peer median (excluding NBIX) $162.51M-3.5%+13.3%25.4%

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.13B1.49B1.89B2.36B2.86B
Cost of Revenue14.3M23.2M39.7M34M52.1M
Gross Profit1.12B1.47B1.85B2.32B2.81B
Gross Margin98.7%98.4%97.9%98.6%98.2%
Research & Development328.1M463.8M565M731.1M1.02B
Selling, General & Admin583.3M752.7M887.6M1.01B1.16B
Operating Expenses1.02B1.22B1.6B1.75B2.19B
Depreciation & Amortization10.9M15.6M21.3M27.1M30.1M
EBITDA138.1M236.6M416.1M639.7M666.6M
EBITDA Margin12.2%15.9%22.0%27.2%23.3%
Operating Income102.5M249M250.9M570.5M619.1M
Operating Margin9.0%16.7%13.3%24.2%21.6%
Interest Income011.2M091M90.3M
Interest Expense25.8M7.1M4.6M126.6M0
Other Income / Expenses(1.1M)(35.1M)81.2M(84.5M)86.3M
Income Before Tax101.4M213.9M332.1M486M705.4M
Pre-Tax Margin8.9%14.4%17.6%20.6%24.7%
Income Tax Expense11.8M59.4M82.4M144.7M226.8M
Net Income89.6M154.5M249.7M341.3M478.6M
Net Margin7.9%10.4%13.2%14.5%16.7%
EPS (Basic)0.951.612.563.404.81
EPS (Diluted)0.921.562.473.294.67
Weighted Avg Shares94.6M95.8M97.7M100.4M99.5M
Weighted Avg Shares (Diluted)97.9M98.9M101M103.7M102.5M

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.